Evaluation of endothelin 1 and N-terminal pro-B-type natriuretic peptide in patients with rheumatoid arthritis
DOI:
https://doi.org/10.15584/ejcem.2025.4.19Keywords:
endothelin 1, N-terminal pro-brain natriuretic peptide retinol–binding protein-4, vitamin D binding proteinAbstract
Introduction and aim. Rheumatoid arthritis (RA) is a chronic disease characterized by synovial inflammation and joint destruction. This study evaluated the novel biomarkers vitamin D binding protein (VDBP), retinol-binding protein 4 (RBP4), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and endothelin-1 (ET-1) for RA diagnosis. To our knowledge, this is the first study to simultaneously assess these biomarkers across different treatment stages in RA, linking systemic inflammation with subclinical cardiovascular involvement.
Material and methods. A case-control study enrolled 61 RA patients [G1 (newly diagnosed, untreated, n=10)], G2 [3 months csDMARDs, n=22], G3 [≥6 months biologic+csDMARDs, n =29]), 27 age/sex-matched healthy controls. The serum levels of VDBP, RBP-4, CRP, NT-proBNP, and ET-1 measured using enzyme-linked immunosorbent assay.
Results. All evaluated biomarkers were significantly elevated in RA patients compared to controls (p<0.0001): RBP-4 (49.172±21.935 vs. 14.006±3.988 ng/mL), VDBP (12.091±3.334 vs. 2.882±1.136 ng/mL), NT-proBNP (1341.787±626.068 vs. 11.452±3.260 pg/mL), ET-1 (14.246±4.031 vs. 3.932±1.422 pg/mL). Subgroup analysis revealed a significantly higher VDBP in newly diagnosed untreated patients (G1:14.455±4.126 ng/mL) than in treated groups (G2:11.379±2.632; G3:11.816±3.269 ng/mL; p<0.05). NT-proBNP peaked in G1 (1789.2±710.81 pg/mL), decreased in csDMARD-treated (G2: 1154.0±537.58 pg/mL), biologic-treated (G3: 1329.96±601.18 pg/mL) group.
Conclusion. VDBP, RBP-4, CRP are effective diagnostic biomarkers of RA. Significant elevations in NT-proBNP and ET-1 levels associated with cardiac complications, correlated with disease activity, and improved with therapy.
Downloads
References
Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11):2857. doi: 10.3390/cells10112857
Mijač S, Banić I, Genc AM, Lipej M, Turkalj M. The Effects of Environmental Exposure on Epigenetic Modifications in Allergic Diseases. Medicina (B Aires). 2024;60(1):110. doi: 10.3390/medicina60010110
Świtała A, Wyszyńska J, Czerwińska K, Dereń K, Podgórska-Bednarz J, Guzik A. Association between body mass and physical activity with quality of life in patients with rheumatoid arthritis. Eur J Clin Exp Med. 2017;(3):200-205. doi: 10.15584/ejcem.2017.3.3
Xiao ZX, Miller JS, Zheng SG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev. 2021;20(2):102743. doi: 10.1016/j.autrev.2020.102743
Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020;110:102400. doi: 10.1016/j.jaut.2019.102400
Qin L ning, Zhang H, Li Q qing, et al. Vitamin D binding protein (VDBP) hijacks twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma. Theranostics. 2024;14(1):436. doi: 10.7150/thno.90322
Fletcher J, Bishop EL, Harrison SR, et al. Autoimmune disease and interconnections with vitamin D. Endocr Connect. 2022;11(3):e210554. doi: 10.1530/EC-21-0554
Rozmus D, Płomiński J, Augustyn K, Cieślińska A. rs7041 and rs4588 polymorphisms in vitamin D binding protein gene (VDBP) and the risk of diseases. Int J Mol Sci. 2022;23(2):933. doi: 10.3390/ijms23020933
Zhang Y, Li S, Zhuo F, et al. Additive Effects of VDBP and 1, 25 (OH) 2D3 on the Viability and Apoptosis of Rheumatoid Arthritis Synovial Fibroblasts. Front Endocrinol (Lausanne). 2021;11:583229. doi: 10.3389/fendo.2020.583229
Nankam PAN, Blüher M. Retinol-binding protein 4 in obesity and metabolic dysfunctions. Mol Cell Endocrinol. 2021;531:111312. doi: 10.1016/j.mce.2021.111312
Steinhoff JS, Lass A, Schupp M. Biological functions of RBP4 and its relevance for human diseases. Front Physiol. 2021;12:659977. doi: 10.3389/fphys.2021.659977
Prasad RR, Mishra N, Kant R, et al. Effect of nonsteroidal anti‐inflammatory drugs (aspirin and naproxen) on inflammation‐associated proteomic profiles in mouse plasma and prostate during TMPRSS2‐ERG (fusion)‐driven prostate carcinogenesis. Mol Carcinog. 2024;63(6):1188-1204. doi: 10.1002/mc.23718
Mun S, Lee J, Park M, Shin J, Lim MK, Kang HG. Serum biomarker panel for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):31. doi: 10.1186/s13075-020-02405-7
Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16(8):491-502. doi: 10.1038/s41569-019-0176-3
Eroglu E, Kocyigit I, Lindholm B. The endothelin system as target for therapeutic interventions in cardiovascular and renal disease. Clin Chim Acta. 2020;506:92-106. doi: 10.1016/j.cca.2020.03.008
Anjankar AP, Lambe SD, Lambe KS. Diagnostic and Prognostic Value of N-Terminal Brain Natriuretic Peptide in Patients of Heart Failure. J Evol Med Dent Sci. 2020;9(31):2176-2181. doi: 10.14260/jemds/2020/474
Fathy HM, Rafat S, Abd-ElAzeem MI, Abdou LM, Abd Elbaset AS, Tantawy M. CRP-Albumin Ratio as A Disease Activity Marker in RA Patients, Its Correlation with Musculoskeletal Sonography. Egypt J Hosp Med. 2023;92(1):5496-5502. doi: 10.21608/ejhm.2023.305791
Cooper J, Pastorello Y, Slevin M. A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Front Immunol. 2023;14:1087571. doi: 10.3389/fimmu.2023.1087571
Allah RMF, El-Refaei KE, Osman EE, Sabry S, Elbagoury IM. Retinol-binding protein 4 as a biomarker of cardiometabolic risk in rheumatoid arthritis. Sci J Al-Azhar Med Fac Girls. 2020;4(2):106-112. doi: 10.4103/sjamf.sjamf_3_20
Pazos-Pérez A, Piñeiro-Ramil M, Franco-Trepat E, et al. The Hepatokine RBP4 Links Metabolic Diseases to Articular Inflammation. Antioxidants. 2024;13(1):124. doi: 10.3390/antiox13010124
Wei Y, Xia N, Zhang W, et al. Serum retinol-binding protein 4 is associated with insulin resistance in patients with early and untreated rheumatoid arthritis. Jt Bone Spine. 2019;86(3):335-341. doi: 10.1016/j.jbspin.2018.07.002
Liu J, Cao X. RBP–RNA interactions in the control of autoimmunity and autoinflammation. Cell Res. 2023;33(2):97-115. doi: 10.1038/s41422-022-00752-5
Bawa FNC, Zhang Y. Retinoic acid signaling in fatty liver disease. Liver Res. 2023;7(3):189-195. doi: 10.1016/j.livres.2023.07.002
Harley J, Clarke BE, Patani R. The interplay of RNA binding proteins, oxidative stress and mitochondrial dysfunction in ALS. Antioxidants. 2021;10(4):552. doi: 10.3390/antiox10040552
Obied MM, Sarhat ER. The Role of Vitamin D-Binding Protein, and Procalcitonin in Patients with Arthritis on Vitamin D. Pharmacogn J. 2024;16(2):431-435. doi: 10.5530/pj.2024.16.68
Cui D, Xu D, Yue S, et al. Recent advances in the pharmacological applications and liver toxicity of triptolide. Chem Biol Interact. 2023,382:110651. doi: 10.5530/pj.2024.16.68
Janoušek J, Pilařová V, Macáková K, et al. Vitamin D: Sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. Crit Rev Clin Lab Sci. 2022;59(8):517-554. doi: 10.1080/10408363.2022.2070595
Delrue C, Speeckaert MM. Vitamin D and vitamin D-binding protein in health and disease. Int J Mol Sci. 2023;24(5):4642. doi: 10.3390/ijms24054642
Cienfuegos AA de, Cantero-Nieto L, García-Gómez JA, et al. AB0294 The effect of smoking on endothelin-1 in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78:1607. doi: 10.1136/annrheumdis-2019-eular.7766
Li R, Yang C, Tang YY, Wang DC, Xu WD, Huang AF. Association between endothelin-1 and systemic lupus erythematosus: insights from a case–control study. Sci Rep. 2023;13(1):15970. doi: 10.1038/s41598-023-43350-0
Rae GA, Henriques MGMO. Endothelins in inflammation. In: Proinflammatory and Antiinflammatory Peptides. CRC Press; 2020:163-202. doi: 10.1201/9781003064695
Sehgal A, Behl T, Singh S, et al. Exploring the pivotal role of endothelin in rheumatoid arthritis. Inflammopharmacology. 2022;30(5):1555-1567. DOI: 10.1007/s10787-022-01051-6
Mangoni AA, Zinellu A. A systematic review and meta-analysis of the endothelial-immune candidate biomarker endoglin in rheumatic diseases. Clin Exp Med. 2024;25(1):4. doi: 10.1007/s10238-024-01519-5
Zhu Y, Xu X. Clinical value of serum NT-proBNP level in the diagnosis of rheumatoid arthritis with cardiac insufficiency. Int J Clin Exp Med. 2020;13(7):5478-5484.
McKechnie DGJ, Papacosta AO, Lennon LT, Welsh P, Whincup PH, Wannamethee SG. Inflammatory markers and incident heart failure in older men: the role of NT-proBNP. Biomark Med. 2021;15(6):413-425. doi: 10.2217/bmm-2020-0669
Hassan NH, Shamsi A, Soufivand P, Bahremand F, Taghaddosi M, Roghani SA. The Relationship of Inflammatory Chemokine, CXCL12, with NT-proBNP: A Marker of Congestive Heart Failure in Rheumatoid Arthritis Patients. J Kermanshah Univ Med Sci. 2023;27(4). doi: 10.5812/jkums-141254.
Shamsi A, Roghani SA, Soufivand P, et al. CXCL9 and NT-proBNP, a notable link between inflammatory mediator and cardiovascular disease biomarker in rheumatoid arthritis. Clin Rheumatol. 2024;43(1):137-145. doi: 10.1007/s10067-023-06826-y
Heslinga M, Teunissen C, Agca R, et al. NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scand J Rheumatol. 2023;52(3):243-249. doi: 10.1080/03009742.2022.2042975.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
